Page last updated: 2024-08-21

benzoxazoles and plx4032

benzoxazoles has been researched along with plx4032 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arnér, ES; Brodin, B; Campbell, J; Drummond, CJ; Higgins, M; Laín, S; McCarthy, AR; Sachweh, MC; Stafford, WC	1
Cheng, Y; Tian, H; Wang, X; Xia, X; Zhang, W	1

Other Studies

2 other study(ies) available for benzoxazoles and plx4032

Article	Year
Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells. Oncotarget, 2015, Jun-30, Volume: 6, Issue:18 Topics: Animals; Antineoplastic Agents; Auranofin; Benzothiazoles; Benzoxazoles; Cell Line, Tumor; Cell Survival; Enzyme Activation; Glutathione; Glutathione Reductase; HCT116 Cells; Humans; Imidazoles; Indoles; Melanoma; Mice; Oxidation-Reduction; Oxidative Stress; Piperazines; Reactive Oxygen Species; Sulfonamides; Sulfones; Thioredoxin Reductase 1; Tumor Suppressor Protein p53; Vemurafenib	2015
A benzoxazole compound as a novel MEK inhibitor for the treatment of RAS/RAF mutant cancer. International journal of cancer, 2019, 07-15, Volume: 145, Issue:2 Topics: Animals; Benzoxazoles; Biological Availability; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Synergism; Female; HT29 Cells; Humans; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Vemurafenib; Xenograft Model Antitumor Assays	2019

Article

Year

Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells.

Oncotarget, 2015, Jun-30, Volume: 6, Issue:18

Topics: Animals; Antineoplastic Agents; Auranofin; Benzothiazoles; Benzoxazoles; Cell Line, Tumor; Cell Survival; Enzyme Activation; Glutathione; Glutathione Reductase; HCT116 Cells; Humans; Imidazoles; Indoles; Melanoma; Mice; Oxidation-Reduction; Oxidative Stress; Piperazines; Reactive Oxygen Species; Sulfonamides; Sulfones; Thioredoxin Reductase 1; Tumor Suppressor Protein p53; Vemurafenib

2015

A benzoxazole compound as a novel MEK inhibitor for the treatment of RAS/RAF mutant cancer.

International journal of cancer, 2019, 07-15, Volume: 145, Issue:2

Topics: Animals; Benzoxazoles; Biological Availability; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Synergism; Female; HT29 Cells; Humans; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Vemurafenib; Xenograft Model Antitumor Assays

2019